The process helps optimize production of a biotherapeutic in a continuous perfusion fermentation process, wherein the bioreactor (fermenter) has an ultrafiltration system that allows impurities to be removed while retaining cells in the bioreactor.
Perfusion bioreactors involve continuous cell culture, feeding, and withdrawal (harvesting) of product and accumulates no waste products, thereby creating a stable cell growth environment.
CMC Biologics chief scientific officer Mads Laustsen said CMC Biologics is witnessing progress of biopharmaceutical manufacturing to the next level.
"This proprietary technology demonstrates that using the impurity filter improved cell density, productivity and product concentration – all critical to helping our customers move their products to market on time and on target," Laustsen added.